Neurocrine Biosciences Competitors

Amgen (NASDAQ:AMGN) and Neurocrine Biosciences (NASDAQ:NBIX) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, institutional ownership, profitability, valuation, analyst recommendations, risk and earnings.

Valuation and Earnings

This table compares Amgen and Neurocrine Biosciences' gross revenue, earnings per share (EPS) and valuation.

Amgen has higher revenue and earnings than Neurocrine Biosciences. Amgen is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Amgen has a beta of 0.76, suggesting that its stock price is 24% less volatile than the S&P 500. Comparatively, Neurocrine Biosciences has a beta of 1.01, suggesting that its stock price is 1% more volatile than the S&P 500.

Institutional and Insider Ownership

75.2% of Amgen shares are held by institutional investors. Comparatively, 95.3% of Neurocrine Biosciences shares are held by institutional investors. 0.4% of Amgen shares are held by insiders. Comparatively, 4.3% of Neurocrine Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Amgen and Neurocrine Biosciences, as provided by MarketBeat.com.

Amgen presently has a consensus price target of $256.4091, indicating a potential upside of 12.94%. Neurocrine Biosciences has a consensus price target of $129.2222, indicating a potential upside of 18.09%. Given Neurocrine Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Neurocrine Biosciences is more favorable than Amgen.

Profitability

This table compares Amgen and Neurocrine Biosciences' net margins, return on equity and return on assets.

Gilead Sciences (NASDAQ:GILD) and Neurocrine Biosciences (NASDAQ:NBIX) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, institutional ownership, profitability, valuation, analyst recommendations, risk and earnings.

Valuation and Earnings

This table compares Gilead Sciences and Neurocrine Biosciences' gross revenue, earnings per share (EPS) and valuation.

Gilead Sciences has higher revenue and earnings than Neurocrine Biosciences. Gilead Sciences is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Gilead Sciences has a beta of 0.51, suggesting that its stock price is 49% less volatile than the S&P 500. Comparatively, Neurocrine Biosciences has a beta of 1.01, suggesting that its stock price is 1% more volatile than the S&P 500.

Institutional and Insider Ownership

76.4% of Gilead Sciences shares are held by institutional investors. Comparatively, 95.3% of Neurocrine Biosciences shares are held by institutional investors. 0.1% of Gilead Sciences shares are held by insiders. Comparatively, 4.3% of Neurocrine Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Gilead Sciences and Neurocrine Biosciences, as provided by MarketBeat.com.

Gilead Sciences presently has a consensus price target of $96.0370, indicating a potential upside of 53.76%. Neurocrine Biosciences has a consensus price target of $129.2222, indicating a potential upside of 18.09%. Given Gilead Sciences' higher probable upside, equities analysts plainly believe Gilead Sciences is more favorable than Neurocrine Biosciences.

Profitability

This table compares Gilead Sciences and Neurocrine Biosciences' net margins, return on equity and return on assets.

Vertex Pharmaceuticals (NASDAQ:VRTX) and Neurocrine Biosciences (NASDAQ:NBIX) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, institutional ownership, profitability, valuation, analyst recommendations, risk and earnings.

Valuation and Earnings

This table compares Vertex Pharmaceuticals and Neurocrine Biosciences' gross revenue, earnings per share (EPS) and valuation.

Vertex Pharmaceuticals has higher revenue and earnings than Neurocrine Biosciences. Vertex Pharmaceuticals is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Vertex Pharmaceuticals has a beta of 0.79, suggesting that its stock price is 21% less volatile than the S&P 500. Comparatively, Neurocrine Biosciences has a beta of 1.01, suggesting that its stock price is 1% more volatile than the S&P 500.

Institutional and Insider Ownership

92.2% of Vertex Pharmaceuticals shares are held by institutional investors. Comparatively, 95.3% of Neurocrine Biosciences shares are held by institutional investors. 0.7% of Vertex Pharmaceuticals shares are held by insiders. Comparatively, 4.3% of Neurocrine Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Vertex Pharmaceuticals and Neurocrine Biosciences, as provided by MarketBeat.com.

Vertex Pharmaceuticals presently has a consensus price target of $291.8462, indicating a potential upside of 38.72%. Neurocrine Biosciences has a consensus price target of $129.2222, indicating a potential upside of 18.09%. Given Vertex Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe Vertex Pharmaceuticals is more favorable than Neurocrine Biosciences.

Profitability

This table compares Vertex Pharmaceuticals and Neurocrine Biosciences' net margins, return on equity and return on assets.

Summary

Vertex Pharmaceuticals beats Neurocrine Biosciences on 11 of the 15 factors compared between the two stocks.

Regeneron Pharmaceuticals (NASDAQ:REGN) and Neurocrine Biosciences (NASDAQ:NBIX) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, institutional ownership, profitability, valuation, analyst recommendations, risk and earnings.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Regeneron Pharmaceuticals and Neurocrine Biosciences, as provided by MarketBeat.com.

Regeneron Pharmaceuticals presently has a consensus price target of $625.8077, indicating a potential upside of 35.15%. Neurocrine Biosciences has a consensus price target of $129.2222, indicating a potential upside of 18.09%. Given Regeneron Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe Regeneron Pharmaceuticals is more favorable than Neurocrine Biosciences.

Profitability

This table compares Regeneron Pharmaceuticals and Neurocrine Biosciences' net margins, return on equity and return on assets.

Volatility and Risk

Regeneron Pharmaceuticals has a beta of 0.3, suggesting that its stock price is 70% less volatile than the S&P 500. Comparatively, Neurocrine Biosciences has a beta of 1.01, suggesting that its stock price is 1% more volatile than the S&P 500.

Institutional and Insider Ownership

85.0% of Regeneron Pharmaceuticals shares are held by institutional investors. Comparatively, 95.3% of Neurocrine Biosciences shares are held by institutional investors. 11.8% of Regeneron Pharmaceuticals shares are held by insiders. Comparatively, 4.3% of Neurocrine Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Regeneron Pharmaceuticals and Neurocrine Biosciences' gross revenue, earnings per share (EPS) and valuation.

Regeneron Pharmaceuticals has higher revenue and earnings than Neurocrine Biosciences. Regeneron Pharmaceuticals is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks.

Summary

Regeneron Pharmaceuticals beats Neurocrine Biosciences on 11 of the 15 factors compared between the two stocks.

Neurocrine Biosciences (NASDAQ:NBIX) and Biogen (NASDAQ:BIIB) are both large-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, profitability, institutional ownership and valuation.

Analyst Ratings

This is a summary of recent ratings and target prices for Neurocrine Biosciences and Biogen, as reported by MarketBeat.

Neurocrine Biosciences currently has a consensus target price of $129.2222, indicating a potential upside of 18.09%. Biogen has a consensus target price of $304.4667, indicating a potential upside of 11.43%. Given Neurocrine Biosciences' stronger consensus rating and higher possible upside, research analysts clearly believe Neurocrine Biosciences is more favorable than Biogen.

Profitability

This table compares Neurocrine Biosciences and Biogen's net margins, return on equity and return on assets.

Risk and Volatility

Neurocrine Biosciences has a beta of 1.01, meaning that its stock price is 1% more volatile than the S&P 500. Comparatively, Biogen has a beta of 0.53, meaning that its stock price is 47% less volatile than the S&P 500.

Insider & Institutional Ownership

95.3% of Neurocrine Biosciences shares are held by institutional investors. Comparatively, 83.5% of Biogen shares are held by institutional investors. 4.3% of Neurocrine Biosciences shares are held by company insiders. Comparatively, 0.5% of Biogen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Neurocrine Biosciences and Biogen's revenue, earnings per share and valuation.

Biogen has higher revenue and earnings than Neurocrine Biosciences. Biogen is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks.

Neurocrine Biosciences (NASDAQ:NBIX) and Alexion Pharmaceuticals (NASDAQ:ALXN) are both large-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, profitability, institutional ownership and valuation.

Analyst Ratings

This is a summary of recent ratings and target prices for Neurocrine Biosciences and Alexion Pharmaceuticals, as reported by MarketBeat.

Neurocrine Biosciences currently has a consensus target price of $129.2222, indicating a potential upside of 18.09%. Alexion Pharmaceuticals has a consensus target price of $153.1250, indicating a potential upside of 0.76%. Given Neurocrine Biosciences' stronger consensus rating and higher possible upside, research analysts clearly believe Neurocrine Biosciences is more favorable than Alexion Pharmaceuticals.

Profitability

This table compares Neurocrine Biosciences and Alexion Pharmaceuticals' net margins, return on equity and return on assets.

Risk and Volatility

Neurocrine Biosciences has a beta of 1.01, meaning that its stock price is 1% more volatile than the S&P 500. Comparatively, Alexion Pharmaceuticals has a beta of 1.33, meaning that its stock price is 33% more volatile than the S&P 500.

Insider & Institutional Ownership

95.3% of Neurocrine Biosciences shares are held by institutional investors. Comparatively, 87.3% of Alexion Pharmaceuticals shares are held by institutional investors. 4.3% of Neurocrine Biosciences shares are held by company insiders. Comparatively, 4.0% of Alexion Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Neurocrine Biosciences and Alexion Pharmaceuticals' revenue, earnings per share and valuation.

Alexion Pharmaceuticals has higher revenue and earnings than Neurocrine Biosciences. Alexion Pharmaceuticals is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks.

Summary

Alexion Pharmaceuticals beats Neurocrine Biosciences on 8 of the 15 factors compared between the two stocks.